Newsletter | April 25, 2024

04.25.24 -- How Continuous Manufacturing Is Shaping Biopharma

SPONSOR

Webinar: Key Elements of Process and Analytical Development to Support Biologics Tech Transfer

Join us on May 13th as our expert panel discusses the intricacies of technology transfer, drawing from real-life case studies. Investigate critical components for success, risk assessment, and effective mitigation strategies. Learn how to optimize your timeline and enhance efficiency in your transfer processes. Click here to learn more.

FEATURED EDITORIAL

A Quality-Led Approach To Drug Production Facility Design

There are important considerations that architects and engineers can miss if they don't include the quality perspective. It's better to involve quality at the outset rather than discover omissions when it's too late.

How Continuous Bioprocessing Is Shaping Modern Biopharma Manufacturing

Continuous processing adoption so far has been slow; however, market research shows demand and capacity will grow significantly over the next four years.

Who The Heck Designed This Biopharm Plant?

The Bozenhardts have seen some absurd, expensive facility design errors in their work. They talk about some of the worst ones here so you can avoid the same mistakes.

INDUSTRY INSIGHTS

Selecting Container Closure Systems With Confidence: Lyophilization

Experts take you through the entire selection process for primary packaging components for lyophilization and provide aspects to consider for all relevant attributes.

Gliding Towards De-Risked Combination Product Development

Learn about the critical role plunger stoppers play in determining a combination drug product's exposure to extractables and leachables.

NEWS HEADLINES

Fresenius Accelerates Momentum In Its (Bio)Pharma Business & Launches Tyenne, Its Third Approved Biosimilar In The U.S

Alvotech & Teva Announce U.S. FDA Approval Of SELARSDI (ustekinumab-aekn), Biosimilar To Stelara (ustekinumab)

Boan Biotech Completes Phase 3 Clinical Trial For Its Aflibercept Intravitreous Injection BA9101 In China, Planning To File A BLA

Alvotech Signs U.S. Agreement To Expand Access For Newly Approved High-Concentration Interchangeable Biosimilar To Humira (adalimumab)

SOLUTIONS

Freeze And Go Solutions For Drug Substances